Nervous System News and Research

Latest Nervous System News and Research

Enrollment complete in ACADIA's pimavanserin Phase III trial for Parkinson's disease psychosis

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the completion of enrollment in its ongoing pivotal Phase III trial with pimavanserin in patients with Parkinson's disease psychosis (PDP).

5 Sep 2012

Newly discovered neuronal pathway plays key role in controlling bone density during adolescence

Researchers at the Hebrew University of Jerusalem have discovered that a neuronal pathway -- part of the autonomic nervous system -- reaches the bones and participates in the control of bone development.

5 Sep 2012

Avanir initiates enrollment in AVP-923 Phase II clinical trial for treatment of agitation in AD patients

Avanir Pharmaceuticals, Inc. today announced the enrollment of the first patient in study AVR-131. The study is a Phase II clinical trial investigating the use of AVP-923 for the treatment of agitation in patients with Alzheimer's disease.

5 Sep 2012

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

BioLineRx Ltd., a biopharmaceutical drug development company, announced today that it has signed an exclusive, worldwide license agreement with Biokine Therapeutics Ltd., a Clal Biotechnology Industries portfolio company, for the development and commercialization of BL-8040 (formerly BKT-140), a Phase II ready drug candidate for the treatment of acute myeloid leukemia (AML), as well as other types of hematological cancer.

4 Sep 2012

FDA approves Novartis’ Exelon Patch to treat mild to moderate AD

The US Food and Drug Administration has approved a higher dose of Exelon Patch (rivastigmine transdermal system) for the treatment of people with mild to moderate Alzheimer's disease.

4 Sep 2012

People with normal blood sugar range may be at increased risk of brain shrinkage

People whose blood sugar is on the high end of the normal range may be at greater risk of brain shrinkage that occurs with aging and diseases such as dementia, according to new research published in the September 4, 2012, print issue of Neurology-, the medical journal of the American Academy of Neurology.

4 Sep 2012

New drug combines photothermia and chemotherapy to help fight cancer

Spanish researchers have developed on a nanometric scale a new drug that combines photothermia and chemotherapy to help fight cancer.

3 Sep 2012

Dysfunctional RyRs play a role in stress-induced cognitive dysfunction

ARMGO Pharma, Inc., a biopharmaceutical company developing innovative small molecule drugs known as "Rycals™," which act on the ryanodine receptor calcium-release channel (RyR), announced that a study published today in the prestigious scientific journal Cell reveals the underlying role of calcium leak through the RyR as an important contributor to stress-induced cognitive dysfunction.

1 Sep 2012

New research about brain and related disorders to be unveiled at Neuroscience 2012

New research about the brain and related disorders will be unveiled at Neuroscience 2012 in New Orleans, Oct. 13-17. Findings will include how the brain weighs complex decisions; progress being made in treating Alzheimer's disease, spinal cord injury, and traumatic brain injury; and novel understanding of how life experiences, diet, and sleep influence brain health and wellness.

31 Aug 2012

FDA approves Ironwood’s LINZESS to treat irritable bowel syndrome with constipation

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. announced today that LINZESS (linaclotide) was approved by the U.S. Food and Drug Administration (FDA) as a once-daily treatment for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

31 Aug 2012

Chronic nerve pain: an interview with Professor Sally Lawson

Chronic nerve pain results from pathological changes within a nerve that appear to be self-sustaining and thus the pain continues for a long time.

30 Aug 2012

FDA grants orphan designation to Aerial BioPharma’s ARL-N05 for treatment of narcolepsy

Aerial BioPharma, a biopharmaceutical company focused on developing biologics and small molecules for conditions in the central nervous system, has received orphan drug designation for its narcolepsy drug in development.

30 Aug 2012

Sleep disorder treatment: an interview with Dr Seth Lederman, President and CEO of Tonix Pharmaceuticals

Sleep disorders are a large area. We are focused on one particular type of sleep disturbance called “non-restorative” sleep. People with this problem do sleep, but they don’t wake up feeling refreshed or feeling that their sleep has had the restorative effects of healthy sleep.

29 Aug 2012

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces positive headline results from the Phase 2 clinical trial of its lead product, EMA401, in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.

28 Aug 2012

ABCD4 and CblF proteins responsible for hereditary vitamin B12 deficiency

Vitamin B12 is vital for cell division, the synthesis of red blood cells and the functioning of the nervous system. Unable to produce the vitamin itself, the human body has to obtain it via animal proteins. So far it has been known that on its way into the cell vitamin B12 is absorbed by little organelles, so-called lysosomes. From there, the vitamin enters the cell interior with the aid of the transport protein CblF, which was discovered by the same research team three years ago.

28 Aug 2012

EphA4 receptor may be promising target for future ALS drug

Leuven scientists (VIB/KU Leuven) are using zebrafish as a model in their search for genes that play a role in the mechanism of amyotrophic lateral sclerosis (ALS). As a result, they have identified a molecule that could be the target for a future ALS treatment.

28 Aug 2012

Nervous System News and Research

Latest Nervous System News and Research

Enrollment complete in ACADIA's pimavanserin Phase III trial for Parkinson's disease psychosis

Newly discovered neuronal pathway plays key role in controlling bone density during adolescence

Avanir initiates enrollment in AVP-923 Phase II clinical trial for treatment of agitation in AD patients

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

FDA approves Novartis’ Exelon Patch to treat mild to moderate AD

People with normal blood sugar range may be at increased risk of brain shrinkage

New drug combines photothermia and chemotherapy to help fight cancer

Dysfunctional RyRs play a role in stress-induced cognitive dysfunction

New research about brain and related disorders to be unveiled at Neuroscience 2012

FDA approves Ironwood’s LINZESS to treat irritable bowel syndrome with constipation

Chronic nerve pain: an interview with Professor Sally Lawson

FDA grants orphan designation to Aerial BioPharma’s ARL-N05 for treatment of narcolepsy

Sleep disorder treatment: an interview with Dr Seth Lederman, President and CEO of Tonix Pharmaceuticals

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

ABCD4 and CblF proteins responsible for hereditary vitamin B12 deficiency

EphA4 receptor may be promising target for future ALS drug

Researchers now add electronic sensors to tissue scaffolds

Neuralstem completes NSI-566 Phase I trial on amyotrophic lateral sclerosis

Pristine Solutions acquires Eaton Scientific Systems

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Nervous System News and Research

Latest Nervous System News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in